Nanotechnology Now - Press Release: "Gold Nanoparticles Shine Brightly in Tumors"

Home > Press > Gold Nanoparticles Shine Brightly in Tumors

Abstract:
Solid gold nanoparticles have long been used to treat rheumatoid arthritis and more recently have shown promise in treating various types of cancer. Now, thanks to work by Shuming Nie, Ph.D., and his colleagues at the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, these same nanoparticles could serve as a powerful tumor-homing beacon for detecting microscopic tumors or even individual malignant cells. The researchers report their findings in the journal Nature Biotechnology.

Gold Nanoparticles Shine Brightly in Tumors

Bethesda , MD | Posted on January 16th, 2008

Starting with colloidal gold—a commercially available suspension of gold nanoparticles—the investigators attached one of several positively charged organic dye molecules to the particles' surfaces. The chosen dye molecules absorb and emit light in the near-infrared region of the spectrum, a portion of the spectrum that passes unabsorbed through biological tissues. The researchers then added a nanometer-thick layer of polyethylene glycol (PEG) to render the construct biocompatible. To their surprise, this coating also made the resulting optical probe incredibly stable under even harsh chemical conditions. More importantly, the optical properties of both the gold nanoparticles and the dye molecules remained constant even after application of the coating. These particles were also nontoxic to cells over periods as long as 6 days.

These initial experiments showed that the coated gold nanoparticles could serve as potent imaging agents for studies of cancer cells, but the real goal of this project was to develop targeted in vivo imaging agents for detecting cancer in humans. To prepare a targeted nanoparticle, the researchers used a version of PEG to which they could chemically link an antibody that binds to epidermal growth factor receptor (EGFR), a molecule overexpressed on many types of tumors. Antibodies and small molecules that bind to EGFR have been approved to treat non-small cell lung cancer.

The investigators injected the targeted nanoparticles into mice with EGFR-positive human head and neck carcinomas and obtained SERS spectra 5 hours later. As control experiments, the researchers injected matching mice with the untargeted nanoparticle. The unique optical spectra of the nanoparticles were easily detected in both sets of animals, but only the targeted nanoparticles accumulated in tumors. In contrast, the untargeted nanoparticles accumulated largely in the liver.

This work, which was supported by the National Cancer Institute's (NCI) Alliance for Nanotechnology in Cancer, is detailed in the paper "In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags." An abstract of this paper is available through PubMed.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: